Related Experiment Video

Updated: Jun 3, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II

Rena Buckstein1, John Kuruvilla, Neil Chua

  • 1Sunnybrook Health Sciences Center, Toronto, ON, Canada. Rena.buckstein@sunnybrook.ca

Leukemia & Lymphoma
|April 6, 2011
PubMed

Insights

Sunitinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor, showed no objective responses in patients with relapsed diffuse large B-cell lymphoma (DLBCL). The trial was stopped early due to lack of efficacy and significant hematologic toxicity.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Limited effective therapies exist for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • Vascular Endothelial Growth Factor Receptor (VEGFR) kinase inhibitors have shown activity in solid tumors.

Purpose of the Study:

  • To evaluate the efficacy and safety of sunitinib in adult patients with relapsed or refractory DLBCL.

Main Methods:

  • Phase II clinical trial involving 19 patients with relapsed/refractory DLBCL.
  • Sunitinib administered orally at 37.5 mg once daily.
  • 17 patients were evaluable for toxicity, 15 for response.

Main Results:

  • No objective responses were observed.
  • Nine patients (60%) achieved stable disease with a median duration of 3.4 months.
  • Grades 3-4 neutropenia (29%) and thrombocytopenia (35%) were significant toxicities.
  • No correlation found between circulating endothelial cell (CEC) counts and tumor burden.

Conclusions:

  • Sunitinib demonstrated no efficacy in relapsed/refractory DLBCL.
  • The drug exhibited higher-than-expected hematologic toxicity in this patient population.
  • The study was discontinued early due to lack of therapeutic benefit.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...